Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: NW-1029; Priralfinamide

Latest Information Update: 29 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Newron Pharmaceuticals; Purdue Biopharma
  • Developer Newron Pharmaceuticals
  • Class Amides; Analgesics; Fluorobenzenes; Small molecules
  • Mechanism of Action N type calcium channel antagonists; Nav1.7 voltage-gated sodium channel inhibitors; NMDA receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Pain; Psychiatric disorders

Highest Development Phases

  • Phase III Neuropathic pain
  • Discontinued Dental pain; Inflammatory pain

Most Recent Events

  • 09 Sep 2015 Phase-II/III development is still ongoing for Neuropathic pain in the EU and India
  • 21 Aug 2012 Discontinued - Phase-II for Dental pain in India (PO)
  • 21 Aug 2012 Discontinued - Phase-II for Dental pain in Romania (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top